Clinical Trial Update: A Clinical Study of DEB-TACE Combined With Surufatinib and Camrelizumab in the Treatment of Inoperable or Metastatic ICC [Phase 2]

View source ↗

Summary

Phase 2 study of DEB-TACE combined with Surufatinib and Camrelizumab for inoperable or metastatic intrahepatic cholangiocarcinoma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Intrahepatic Cholangiocarcinoma

Drugs mentioned

• Camrelizumab (camrelizumab)
• DEB-TACE (drug-eluting bead transarterial chemoembolization)
• Surufatinib (Surufatinib)

Snippet

Sponsor: Tongji Hospital | Conditions: Intrahepatic Cholangiocarcinoma | Phase 2 | Status: COMPLETED